These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7086673)

  • 1. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man.
    Küpfer A; Desmond PV; Schenker S; Branch RA
    J Pharmacol Exp Ther; 1982 Jun; 221(3):590-7. PubMed ID: 7086673
    [No Abstract]   [Full Text] [Related]  

  • 2. Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.
    Akrawi SH; Wedlund PJ
    Eur J Drug Metab Pharmacokinet; 1989; 14(4):269-78. PubMed ID: 2633921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective metabolism of mephenytoin in man.
    Küpfer A; Roberts RK; Schenker S; Branch RA
    J Pharmacol Exp Ther; 1981 Jul; 218(1):193-9. PubMed ID: 7241378
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
    Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
    J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased systemic availability of drugs during acute ethanol intoxication: studies with mephenytoin in the dog.
    Zysset T; Preisig R; Bircher J
    J Pharmacol Exp Ther; 1980 Apr; 213(1):173-8. PubMed ID: 7188964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselectivity of differential routes of drug metabolism: the fate of the enantiomers of [14C]mephenytoin in the dog.
    Küpfer A; Bircher J
    J Pharmacol Exp Ther; 1979 May; 209(2):190-5. PubMed ID: 438994
    [No Abstract]   [Full Text] [Related]  

  • 7. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.
    Küpfer A; Patwardhan R; Ward S; Schenker S; Preisig R; Branch RA
    J Pharmacol Exp Ther; 1984 Jul; 230(1):28-33. PubMed ID: 6747829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mephenytoin stereoselective elimination in the rat: I. Enantiomeric disposition following intravenous administration.
    Akrawi SH; Wedlund PJ
    Eur J Drug Metab Pharmacokinet; 1989; 14(3):195-200. PubMed ID: 2612516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
    Küpfer A; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):414-8. PubMed ID: 4042524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of mephenytoin and ethotoin.
    Troupin AS; Friel P; Lovely MP; Wilensky AJ
    Ann Neurol; 1979 Nov; 6(5):410-4. PubMed ID: 42344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mephenytoin hydroxylation deficiency: kinetics after repeated doses.
    Küpfer A; Desmond P; Patwardhan R; Schenker S; Branch RA
    Clin Pharmacol Ther; 1984 Jan; 35(1):33-9. PubMed ID: 6690169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
    Küpfer A; Brilis GM; Watson JT; Harris TM
    Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog.
    Küpfer A; Bircher J; Preisig R
    J Pharmacol Exp Ther; 1977 Dec; 203(3):493-9. PubMed ID: 925954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.
    Andersson T; Regårdh CG; Dahl-Puustinen ML; Bertilsson L
    Ther Drug Monit; 1990 Jul; 12(4):415-6. PubMed ID: 2396316
    [No Abstract]   [Full Text] [Related]  

  • 15. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
    Jacqz E; Hall SD; Branch RA; Wilkinson GR
    Clin Pharmacol Ther; 1986 Jun; 39(6):646-53. PubMed ID: 3709029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol.
    García Quetglas E; Azanza JR; Cardenas E; Sádaba B; Campanero MA
    Biopharm Drug Dispos; 2007 Jan; 28(1):19-33. PubMed ID: 17061296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man.
    Küpfer A; Lawson J; Branch RA
    Epilepsia; 1984 Feb; 25(1):1-7. PubMed ID: 6420144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereochemical aspects of the metabolism of 5-ethyl-5-phenylhydantoin (Nirvanol) in the dog.
    Maguire JH; Kraus BL; Butler TC; Dudley KH
    Drug Metab Dispos; 1981; 9(5):393-401. PubMed ID: 6117436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite, nirvanol.
    Wells PG; Küpfer A; Lawson JA; Harbison RD
    J Pharmacol Exp Ther; 1982 Apr; 221(1):228-34. PubMed ID: 7062285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The non-human primate: a possible model for human genetically determined polymorphisms in oxidative drug metabolism.
    Jacqz E; Billante C; Moysan F; Mathieu H
    Mol Pharmacol; 1988 Aug; 34(2):215-7. PubMed ID: 3412323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.